Search for: "Two's Company, Inc." Results 741 - 760 of 27,160
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Jan 2024, 9:01 pm by renholding
Kraft Heinz The $450 million settlement against Kraft Heinz arises out of the tumultuous merger in 2015 that created the company. [read post]
23 Jan 2024, 10:34 am by Eric Goldman
Two recent cases illustrate the extent to which courts today are willing to enforce this regime. [read post]
23 Jan 2024, 5:50 am by Michael C. Dorf
In my two previous essays (here and here) on last week's oral arguments in Relentless, Inc. v. [read post]
22 Jan 2024, 3:32 am by Peter J. Sluka
  For a successful challenge to a dilutive recapitalization, consider the 2021 decision of New York County Justice Andrew Borrok, 15882 Can., Inc. v Money.Net, Inc., 2021 N.Y. [read post]
22 Jan 2024, 1:10 am by INFORRM
The ICO has fined two home improvement companies for marketing phone calls to people on the UK’s “do not call” register. [read post]
19 Jan 2024, 10:59 am by Keith Szeliga
The number of indirect pools can range from as few as one or two at a small professional services firm to more than a hundred at a diversified defense contractor. [read post]
19 Jan 2024, 7:37 am by The White Law Group
(CRD#:16783), LAGUNA HILLS, CA B, 01/23/2008 – 12/31/2013, BERTHEL, FISHER & COMPANY FINANCIAL SERVICES, INC. [read post]
19 Jan 2024, 7:09 am by Melissa Tremblay
  These settlements included:   BioTel and LifeWatch– Overbilling Federal Health Care Programs $13 Million Settlement  BioTelemetry, Inc. and related company LifeWatch Services, Inc., two ambulatory heart monitoring companies, paid $13 million to settle allegations that they overbilled federal health programs for mobile cardiac telemetry services. Our client revealed Defendants’ fraud by filing a complaint under… [read post]
Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals International AG, and Takeda Pharmaceuticals America, Inc.) sued to enjoin Defendants from marketing generic versions on the basis of inducing and/or contributorily infringing various patents, including U.S. [read post]